{
  "kind": "treatment",
  "slug": "sulpiride-dogmatil",
  "type": "medication",
  "name": "Sulpiride",
  "summary": "Sulpiride (Dogmatil) is a benzamide antipsychotic used to treat schizophrenia, depression, and some gastrointestinal disorders.",
  "description": "Sulpiride, marketed under brand names including Dogmatil, is a substituted benzamide antipsychotic with selective dopamine D2 and D3 receptor antagonism. At higher doses, it is used to treat schizophrenia and other psychotic disorders. At low doses, it has antidepressant and prokinetic effects and is sometimes prescribed for dysthymia, functional dyspepsia, and vertigo. It is not widely available in the United States but is used in parts of Europe, Asia, and South America.",
  "category": "medications/psychiatry",
  "tags": [
    "antipsychotic",
    "benzamide",
    "schizophrenia",
    "depression",
    "functional dyspepsia"
  ],
  "metadata": {
    "drug_classes": [
      "Benzamide antipsychotic"
    ],
    "therapeutic_categories": [
      "Psychiatry",
      "Gastroenterology"
    ],
    "mechanism_categories": [
      "Dopamine Blocker"
    ],
    "administration_routes": [
      "Oral",
      "Injection"
    ],
    "prescription_status": "Prescription only",
    "controlled_substance": false,
    "generic_available": true,
    "brand_names": [
      "Dogmatil",
      "Dolmatil"
    ],
    "age_groups": [
      "Adult",
      "Geriatric"
    ],
    "treatment_duration": [
      "Short-term",
      "Long-term maintenance"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Gastroenterology",
      "Primary care"
    ],
    "fda_approval_year": 1968
  },
  "clinical_metadata": {
    "primary_indications": [
      "Psychosis",
      "Depression",
      "Other"
    ],
    "off_label_uses": [
      "Negative symptoms of schizophrenia",
      "Somatoform disorders"
    ],
    "contraindications": [
      "Pheochromocytoma",
      "Prolactin-dependent tumors (e.g., pituitary prolactinoma, breast cancer)",
      "Hypersensitivity to sulpiride or formulation components",
      "Acute porphyria"
    ],
    "monitoring_required": [
      "Psychiatric symptoms and response",
      "Extrapyramidal symptoms",
      "Prolactin levels with prolonged use",
      "Weight and metabolic parameters"
    ],
    "efficacy_rating": {
      "Schizophrenia": 2,
      "Depression": 2,
      "Functional dyspepsia": 2
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "sulpiride",
      "Dogmatil",
      "benzamide antipsychotic"
    ],
    "synonyms": [
      "Dogmatil",
      "Dolmatil",
      "sulpiride hydrochloride"
    ],
    "common_misspellings": [
      "sulperide",
      "sulpirid",
      "sulpiried"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Schizophrenia and other psychotic disorders",
        "Depressive disorders (low-dose)",
        "Functional dyspepsia",
        "Vertigo"
      ]
    },
    {
      "type": "mechanism",
      "text": "Selectively antagonizes dopamine D2 and D3 receptors, reducing dopaminergic neurotransmission in mesolimbic pathways (antipsychotic effect) and modulating activity in other brain regions and the gastrointestinal tract."
    },
    {
      "type": "dosing",
      "adult": {
        "oral": "Schizophrenia: 400–800 mg/day in divided doses, up to 1600 mg/day. Depression/functional dyspepsia: 50–150 mg/day in divided doses."
      },
      "pediatric": {
        "oral": "Not routinely recommended."
      }
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: 50 mg, 100 mg, 200 mg",
        "Capsules: 50 mg, 100 mg",
        "Injection (IM): 100 mg/2 mL"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Psychiatric symptom improvement may be observed within 1–2 weeks; gastrointestinal benefits may occur within days."
    },
    {
      "type": "adverse_effects",
      "common": [
        "somnolence",
        "insomnia",
        "extrapyramidal symptoms",
        "hyperprolactinemia",
        "weight gain"
      ],
      "less_common": [
        "hypotension",
        "dry mouth",
        "constipation"
      ],
      "serious": [
        "neuroleptic malignant syndrome",
        "tardive dyskinesia",
        "QT prolongation"
      ]
    },
    {
      "type": "warnings",
      "other": [
        "May cause hyperprolactinemia; monitor with prolonged use",
        "Use caution in patients with cardiovascular disease or risk factors for QT prolongation",
        "Increased mortality in elderly patients with dementia-related psychosis",
        "Avoid abrupt discontinuation to reduce relapse risk"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Levodopa",
          "risk": "Reduced antiparkinsonian effect",
          "action": "Avoid combination"
        },
        {
          "with": "Alcohol and CNS depressants",
          "risk": "Additive sedation",
          "action": "Avoid or monitor closely"
        },
        {
          "with": "QT-prolonging drugs",
          "risk": "Additive QT prolongation",
          "action": "Avoid combination"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Psychiatric status and symptom control",
        "Extrapyramidal symptoms",
        "Weight, BMI, and metabolic labs",
        "Prolactin levels"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use only if benefits outweigh potential risks; risk of neonatal extrapyramidal or withdrawal symptoms if used late in pregnancy.",
      "lactation": "Excreted in breast milk; monitor infant for sedation or feeding issues if use is unavoidable.",
      "geriatrics": "Increased sensitivity to hypotension and sedation; start with lower doses."
    },
    {
      "type": "tapering",
      "text": "Gradually reduce dose over 1–2 weeks to minimize withdrawal symptoms or relapse."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Low doses may have antidepressant and prokinetic effects",
        "Not approved in the United States; available in select countries",
        "Prolactin elevation is more prominent compared to many other antipsychotics"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "PubChem - Sulpiride",
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/Sulpiride"
        },
        {
          "label": "NHS - Sulpiride",
          "url": "https://www.nhs.uk/medicines/sulpiride/"
        },
        {
          "label": "Dogmatil Product Information",
          "url": "https://www.medicines.org.uk/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Sulpiride (Dogmatil) - Uses, Dosage, Side Effects, and Warnings",
    "description": "Sulpiride (Dogmatil) is a benzamide antipsychotic used for schizophrenia, depression, and functional dyspepsia. Learn about dosing, side effects, interactions, and precautions."
  }
}
